Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207905 · ClinicalTrials.gov registry record
Evaluation of the Healthy Michigan Plan Section 1115 Community Engagement Requirement Waiver
A clinical trial, sponsored by University of Michigan.
- Terminated
- Registry status
- 892
- Enrollment target
NCT04207905: Clinical Trial study, sponsored by University of Michigan.
NCT04207905 is a clinical trial that was terminated before completion, run by University of Michigan. The registered enrollment target is 892 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04207905 was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- 892 participants
- Enrollment target
Study Summary
The Centers for Medicare \& Medicaid Services (CMS) approved the renewal of the Healthy Michigan Plan (HMP) Section 1115 Demonstration Waiver on December 21, 2018, for the period January 1, 2019-December 31, 2023. This waiver provides approval for the state to require Medicaid expansion beneficiaries ages 19-62 to complete and report 80 hours per month of community engagement as a condition of eligibility, among other waiver provisions, beginning January 1, 2020. Community engagement activities include employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service. The State of Michigan will implement a randomized controlled trial (RCT) to evaluate the impact of community engagement requirements on Medicaid enrollment, health insurance coverage, self-reported health status, access to and utilization of health services, earnings, and employment, compared to a control group of HMP enrollees exempted from the community engagement requirement for purposes of the evaluation.
Primary Outcome
Insurance coverage (self-reported uninsurance, employer-sponsored insurance, other types of insurance)
Interventions
- OTHER Healthy Michigan Plan (HMP) coverage with work requirements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 892 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2020-03-04 |
Why NCT04207905 stopped before completion
NCT04207905 is an observational study that tracks outcomes without assigning an intervention. The registered 892 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Healthy Michigan Plan (HMP) coverage with work requirements is the first listed.
NCT04207905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04207905 about?
NCT04207905 is a clinical study titled "Evaluation of the Healthy Michigan Plan Section 1115 Community Engagement Requirement Waiver". The Centers for Medicare \& Medicaid Services (CMS) approved the renewal of the Healthy Michigan Plan (HMP) Section 1115 Demonstration Waiver on December 21, 2018, for the period January 1, 2019-December 31, 2023. This waiver provides approval for the state to require Medicaid expansion beneficiarie...
What is the current status of trial NCT04207905?
This trial is currently terminated. The enrollment target is 892 participants. The study started on 2020-01-01. Estimated completion is 2020-03-04.
What interventions are being tested in trial NCT04207905?
The interventions under investigation include: Healthy Michigan Plan (HMP) coverage with work requirements (OTHER).
Who is sponsoring clinical trial NCT04207905?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI